LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 2 of total 2

Search options

  1. Article ; Online: Timing and temporal trends of influenza and pertussis vaccinations during pregnancy in three Australian jurisdictions: The Links2HealthierBubs population-based linked cohort study, 2012-2017.

    Mchugh, Lisa / Van Buynder, Paul / Sarna, Mohinder / Andrews, Ross M / Moore, Hannah C / Binks, Michael J / Pereira, Gavin / Blyth, Christopher C / Lust, Karin / Foo, Damien / Regan, Annette K

    The Australian & New Zealand journal of obstetrics & gynaecology

    2022  Volume 63, Issue 1, Page(s) 27–33

    Abstract: Background: Antenatal inactivated influenza (IIV) and pertussis-containing vaccines (dTpa) offer protection against severe respiratory infections for pregnant women and infants <6 months of age. Both vaccines are recommended in pregnancy; however, ... ...

    Abstract Background: Antenatal inactivated influenza (IIV) and pertussis-containing vaccines (dTpa) offer protection against severe respiratory infections for pregnant women and infants <6 months of age. Both vaccines are recommended in pregnancy; however, little is known about temporal or jurisdictional trends and predictors of uptake.
    Aims: To identify gaps and predictors of IIV and/or dTpa vaccinations in Australian pregnancies from 2012 to 2017.
    Materials and methods: We conducted a probabilistically linked, multi-jurisdictional population-based cohort study, drawing from perinatal data collections and immunisation databases. We used a generalised linear mixed model with a random effect term to account for clustering of multiple pregnancies within mothers, to calculate vaccination uptake, and identify predictors of uptake by maternal demographic, pregnancy, and health characteristics.
    Results: Of 591 868 unique pregnancies, IIV uptake was 15%, dTpa 27% and 12% received both vaccines. Pertussis vaccinations in First Nations pregnancies were 20% lower than non-Indigenous pregnancies; dTpa was strongly associated with IIV uptake (risk ratio (RR): 8.60, 95% CI 8.48-8.73). This trend was temporally and jurisdictionally consistent. First Nations women were more likely to have had IIV in pregnancy before the introduction of dTpa in the pregnancy program: (RR: 1.48, 95% CI 1.40-1.57), but less likely after dTpa implementation (RR: 0.78, 95% CI 0.76-0.80).
    Conclusions: Inequity in vaccine uptake between First Nations and non-Indigenous pregnancies, and dismal rates of vaccination in pregnancy overall need urgent review, particularly before the next influenza pandemic or pertussis outbreak. If antenatal dTpa is driving IIV uptake, changes in antenatal healthcare practices are needed to ensure vaccines are offered equitably and optimally to protect against infection.
    MeSH term(s) Infant ; Female ; Pregnancy ; Humans ; Influenza, Human/epidemiology ; Influenza, Human/prevention & control ; Whooping Cough/epidemiology ; Whooping Cough/prevention & control ; Australia/epidemiology ; Cohort Studies ; Influenza Vaccines ; Vaccination ; Pertussis Vaccine ; Pregnancy Complications, Infectious/epidemiology ; Pregnancy Complications, Infectious/prevention & control ; Pregnancy, Multiple
    Chemical Substances Influenza Vaccines ; Pertussis Vaccine
    Language English
    Publishing date 2022-06-13
    Publishing country Australia
    Document type Journal Article
    ZDB-ID 390815-x
    ISSN 1479-828X ; 0004-8666
    ISSN (online) 1479-828X
    ISSN 0004-8666
    DOI 10.1111/ajo.13548
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article: Combination treatment with ionising radiation and gefitinib ('Iressa', ZD1839), an epidermal growth factor receptor (EGFR) inhibitor, significantly inhibits bladder cancer cell growth in vitro and in vivo.

    Colquhoun, A J / Mchugh, L A / Tulchinsky, E / Kriajevska, M / Mellon, J K

    Journal of radiation research

    2007  Volume 48, Issue 5, Page(s) 351–360

    Abstract: Purpose: External beam radiotherapy (EBRT) is the principal bladder-preserving monotherapy for muscle-invasive bladder cancer. Seventy percent of muscle-invasive bladder cancers express epidermal growth factor receptor (EGFR), which is associated with ... ...

    Abstract Purpose: External beam radiotherapy (EBRT) is the principal bladder-preserving monotherapy for muscle-invasive bladder cancer. Seventy percent of muscle-invasive bladder cancers express epidermal growth factor receptor (EGFR), which is associated with poor prognosis. Ionising radiation (IR) stimulates EGFR causing activation of cytoprotective signalling cascades and thus may be an underlying cause of radioresistance in bladder tumours.
    Materials and methods: We assessed the ability of IR to activate EGFR in bladder cancer cells and the effect of the anti-EGFR therapy, gefitinib on potential radiation-induced activation. Subsequently we assessed the effect of IR on signalling pathways downstream of EGFR. Finally we assessed the activity of gefitinib as a monotherapy, and in combination with IR, using clonogenic assay in vitro, and a murine model in vivo.
    Results: IR activated EGFR and gefitinib partially inhibited this activation. Radiation-induced activation of EGFR activated the MAPK and Akt pathways. Gefitinib partially inhibited activation of the MAPK pathway but not the Akt pathway. Treatment with combined gefitinib and IR significantly inhibited bladder cancer cell colony formation more than treatment with gefitinib alone (p = 0.001-0.03). J82 xenograft tumours treated with combined gefitinib and IR showed significantly greater growth inhibition than tumours treated with IR alone (p = 0.04).
    Conclusions: Combining gefitinib and IR results in significantly greater inhibition of invasive bladder cancer cell colony formation in vitro and significantly greater tumour growth inhibition in vivo. Given the high frequency of EGFR expression by bladder tumours and the low toxicity of gefitinib there is justification to translate this work into a clinical trial.
    MeSH term(s) Animals ; Antineoplastic Agents/administration & dosage ; Cell Proliferation/drug effects ; Cell Proliferation/radiation effects ; ErbB Receptors/antagonists & inhibitors ; Gefitinib ; Humans ; Mice ; Mice, Inbred BALB C ; Mice, Nude ; Quinazolines/administration & dosage ; Radiotherapy, Adjuvant/methods ; Treatment Outcome ; Tumor Cells, Cultured ; Urinary Bladder Neoplasms/drug therapy ; Urinary Bladder Neoplasms/pathology ; Urinary Bladder Neoplasms/radiotherapy
    Chemical Substances Antineoplastic Agents ; Quinazolines ; ErbB Receptors (EC 2.7.10.1) ; Gefitinib (S65743JHBS)
    Language English
    Publishing date 2007-07-03
    Publishing country England
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 603983-2
    ISSN 0449-3060
    ISSN 0449-3060
    DOI 10.1269/jrr.07014
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top